Q3 2025 Earnings Report November 6, 2025 | Nasdaq: COLL Healthier people. Stronger communities. Forward-Looking Statements This presentation contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. We may, in some cases, use terms such as "predicts," "forecasts," "believes," "potential," "proposed," "continue," "estimates," "anticipates," "expects," "plans," "intends," "may," "could," "might," "should" or other words that convey uncertainty of future ev ...

Financial Performance - Product revenues for Q3 2025 reached $209.4 million, a 31.5% increase from $159.3 million in Q3 2024[19] - Gross profit for the nine months ended September 30, 2025, was $334.9 million, compared to $279.1 million for the same period in 2024, reflecting a 19.9% increase[19] - Net income for Q3 2025 was $31.5 million, significantly up from $9.3 million in Q3 2024, representing a 237.5% increase[19] - The company reported a comprehensive income of $31.5 million for Q3 2025, compared to $9.9 million in Q3 2024, reflecting a 217.4% increase[22] - Net income for the three months ended September 30, 2025, was $31,507, compared to $9,335 for the same period in 2024, representing a year-over-year increase of 237%[70] - The effective tax rate for the three months ended September 30, 2025, was 27.5%, a decrease from 40.1% in the same period of 2024[173] Assets and Liabilities - Total current assets increased to $613.9 million as of September 30, 2025, compared to $482.3 million at the end of 2024, marking a 27.3% growth[16] - Total liabilities decreased to $1.33 billion as of September 30, 2025, down from $1.43 billion at the end of 2024, a reduction of 7.8%[16] - Cash and cash equivalents rose to $150.1 million as of September 30, 2025, compared to $70.6 million at the end of 2024, an increase of 112.5%[16] - Total assets measured at fair value as of September 30, 2025, amounted to $173,154 million, an increase from $130,344 million as of December 31, 2024[74] - The fair value of the Company's 2.875% convertible senior notes due in 2029 was $286,491 million with a net carrying value of $237,950 million as of September 30, 2025[78] Revenue Recognition and Accounting - The Company recognized revenue when a customer obtains control of promised goods, typically upon delivery, with payment received 30 to 90 days after[43] - The Company bases its estimates of variable consideration on historical data, including timing of rebates and returns, pricing adjustments, and quantity of products expected to be rebated or returned[45] - Provisions for product returns are based on product-level return rates and are estimated at the time of revenue recognition[47] - The Company provides an 18-month return window for customers, starting six months prior to expiration and ending twelve months after[48] - The Company disaggregates revenue from contracts with customers by product to reflect how economic factors affect revenue and cash flows[55] Acquisition and Intangible Assets - The Company closed its acquisition of Ironshore Therapeutics Inc. on September 3, 2024, acquiring the Jornay PM product, which has commercial approval in the U.S.[27] - The Ironshore Acquisition was completed on September 3, 2024, for a total consideration of approximately $306,104, which includes $276,888 in cash and $29,216 in deferred and contingent payments[62] - The fair value of acquired intangible assets from the Ironshore Acquisition was recorded at $635,000, amortized over a useful life of 7.7 years[65] - The total identifiable net assets acquired in the Ironshore Acquisition amounted to $294,036, with goodwill recorded at $12,068[64] Operating Expenses - Operating expenses for the nine months ended September 30, 2025, were $216.0 million, up from $147.3 million in the same period of 2024, a 46.7% increase[19] - Total commercial expenses for the three months ended September 30, 2025, were $36.93 million, up from $20.08 million in the same period of 2024, indicating an increase of 83.5%[177] - Selling, general and administrative expenses increased by $69.9 million to $217.2 million in the 2025 Period, primarily due to higher salaries and marketing expenses following the Ironshore Acquisition[210] - Salaries, wages, and benefits rose by $42.2 million, driven by additional headcount from the Ironshore Acquisition and executive transitions[210] - Sales and marketing expenses increased by $34.7 million to support the commercialization of Jornay PM post-Ironshore Acquisition[210] Stock and Shareholder Activities - The total shareholders' equity as of June 30, 2025, was $232.21 million, reflecting a net income of $31.51 million for the period[119] - The company repurchased shares under the Accelerated Share Repurchase agreement, resulting in a reduction of $25.01 million in treasury stock[119] - The company repurchased 2,704,830 shares at a weighted-average price of $31.43 per share, totaling $85,025 under the 2024-2025 Repurchase Program[127] - The 2025 Plan has 3,257,241 shares available for issuance as of September 30, 2025, with an aggregate of 1,600,000 shares authorized for issuance[121] - The company has not yet repurchased shares under the 2025-2026 Repurchase Program, leaving $150,000 available for share repurchases as of September 30, 2025[129] Legal Proceedings - The company is currently involved in multiple legal proceedings, including patent infringement lawsuits related to Xtampza ER and Nucynta, but is unable to estimate potential losses at this stage[146][150] - The company plans to vigorously defend against ongoing litigation, including the Merger Litigations related to the BDSI Acquisition, which allege violations of the Exchange Act[156][159] - The company has settled a patent infringement dispute with Aquestive Therapeutics for a one-time payment of $8,500, recognized as an expense in the consolidated statements of operations for the year ended December 31, 2023[155] - The company has received subpoenas related to opioid sales and marketing practices and is cooperating with investigations from several state Attorney General offices[151][152] Product Performance - Jornay PM generated $41,802 in revenue for the three months ended September 30, 2025, compared to $7,961 in the same period of 2024, reflecting a significant increase of 424%[56] - For the nine months ended September 30, 2025, product revenues were $575.1 million, a 27.9% increase from $449.5 million in the same period of 2024, driven by strong performance from Jornay PM and Nucynta Products[204] - Gross profit for the three months ended September 30, 2025, was $129.2 million, compared to $96.8 million in the same period of 2024, reflecting a gross margin improvement[189] - Jornay PM revenue increased by $33.8 million due to its acquisition from Ironshore Therapeutics in September 2024[191] - Nucynta Products revenue rose by $9.7 million, attributed to lower gross-to-net adjustments and higher gross prices, despite lower sales volume[192]

Group 1 - The article does not provide any specific content or key points related to a company or industry [1]

Financial Performance - Generated record quarterly net revenue of $209.4 million, up 31% year-over-year[1] - Generated record quarterly pain portfolio net revenue of $167.6 million, up 11% year-over-year, with all three core products growing year-over-year[5] - Generated Nucynta franchise net revenue of $54.8 million, up 21% year-over-year[8] - Adjusted EBITDA for Q3 2025 was $133.0 million, representing a 27% increase year-over-year[10] - GAAP net income for Q3 2025 was $31.5 million, with $1.00 GAAP earnings per share (basic)[9] - Net income for Q3 2025 was $31.5 million, significantly up from $9.3 million in Q3 2024, marking a 237.5% increase[28] - Adjusted EBITDA for Q3 2025 was $133.0 million, compared to $105.1 million in Q3 2024, representing a 26.5% increase[30] - The company reported a basic earnings per share of $1.00 for Q3 2025, compared to $0.29 for Q3 2024, reflecting a significant increase[28] Revenue Guidance - Raised full-year 2025 net revenue guidance to a range of $775 to $785 million and adjusted EBITDA guidance to a range of $460 to $470 million[1][6] - Collegium Pharmaceutical anticipates continued growth in product revenues and adjusted EBITDA for 2025, driven by market expansion and new product launches[1] Cash and Assets - Ended Q3'25 with cash, cash equivalents, and marketable securities of $285.9 million[1] - Total assets as of September 30, 2025, were $1.607 billion, a decrease from $1.664 billion as of December 31, 2024[26] - Cash and cash equivalents increased to $150.1 million from $70.6 million at the end of 2024, showing a 112.5% increase[26] Operating Expenses - Adjusted operating expenses for Q3 2025 were $55.7 million, representing a 60% increase year-over-year[9] - Selling, general and administrative expenses for Q3 2025 were $67.1 million, up from $62.0 million in Q3 2024, indicating an 8.5% increase[28] Product Performance - Generated record quarterly Jornay PM® net revenue of $41.8 million, with prescriptions growing by 20% year-over-year[5] - Jornay PM prescribers reached an all-time high of 27,700 healthcare providers, up 22% year-over-year[5] - Product revenues for Q3 2025 reached $209.4 million, a 31.5% increase from $159.3 million in Q3 2024[28] - Gross profit for Q3 2025 was $129.2 million, compared to $96.8 million in Q3 2024, reflecting a 33.4% year-over-year growth[28] Strategic Focus - The company is focused on managing relationships with licensors and maintaining regulatory approvals to support future growth[1]

Core Insights - Collegium Pharmaceutical, Inc. reported record quarterly net revenue of $209.4 million, representing a 31% increase year-over-year [1][11] - The company raised its full-year 2025 net revenue guidance to a range of $775 to $785 million and adjusted EBITDA guidance to a range of $460 to $470 million [1][8] - The company ended Q3 2025 with cash, cash equivalents, and marketable securities totaling $285.9 million [1] ADHD Business Highlights - Jornay PM net revenue reached a record $41.8 million, with prescriptions growing by 20% year-over-year [1][7] - The number of healthcare providers prescribing Jornay PM increased by 22% year-over-year, reaching an all-time high of 27,700 [7] Pain Portfolio Highlights - The pain portfolio generated record net revenue of $167.6 million, up 11% year-over-year, with all three core products showing growth [1][7] - Belbuca net revenue was $58.3 million, up 10% year-over-year, while Xtampza ER net revenue was $50.5 million, up 2% year-over-year [7] - Nucynta Franchise net revenue increased by 21% year-over-year, totaling $54.8 million [7] Financial Results - GAAP net income for Q3 2025 was $31.5 million, with GAAP earnings per share of $1.00 (basic) and $0.84 (diluted) [11][29] - Adjusted EBITDA for the quarter was $133.0 million, a 27% increase from the previous year [11][32] - The company generated $78.4 million in cash from operations during the quarter [11] Corporate Updates - The company has authorized a new share repurchase program to buy back up to $150 million of common stock through December 31, 2026 [10] - Collegium celebrated its 10-year anniversary as a publicly traded company on the Nasdaq Stock Market [10]

Core Insights - Paris Hilton collaborates with Collegium Pharmaceutical to share her ADHD journey and encourage others to seek treatment [3][5][6] - ADHD affects approximately 15.5 million adults and 6.5 million children in the U.S., with an estimated 70% of adults experiencing symptoms into adulthood [4] Company Overview - Collegium Pharmaceutical, Inc. is a diversified biopharmaceutical company focused on improving the lives of individuals with serious medical conditions, particularly in pain management and neuropsychiatry [16][17] - The company’s leading product, JORNAY PM, is a treatment for ADHD that is taken at night and lasts throughout the day [6][7] Product Information - JORNAY PM is indicated for the treatment of ADHD in patients aged 6 years and older, helping to increase attention and decrease impulsiveness and hyperactivity [7] - The medication contains methylphenidate and is classified as a federally controlled substance due to its potential for abuse [8][9] Treatment Journey - Paris Hilton was diagnosed with ADHD as a young adult and has since worked with her healthcare provider to find an effective treatment plan, ultimately choosing JORNAY PM [6][5] - The collaboration aims to raise awareness about ADHD and the importance of finding suitable treatment options [3][5]

Core Viewpoint - Collegium Pharmaceutical, Inc. is set to report its third quarter 2025 financial results on November 6, 2025, before market opening, followed by a live conference call at 8:00 a.m. ET [1]. Company Overview - Collegium Pharmaceutical is focused on becoming a leading, diversified biopharmaceutical company dedicated to improving the lives of individuals with serious medical conditions [3]. - The company has a strong portfolio in responsible pain management medications and is expanding its neuropsychiatry business, particularly with Jornay PM®, a unique treatment for ADHD [3]. - Collegium's strategy emphasizes the growth of its commercial portfolio, with Jornay PM as the primary growth driver, and aims to deploy capital in a disciplined manner [3].

Core Insights - Collegium Pharmaceutical, Inc. is presenting real-world data on its ADHD treatment product, Jornay PM, at the AACAP and NEI conferences, emphasizing its commitment to the ADHD community [1][2] Group 1: Product Information - Jornay PM is a CNS stimulant used for treating ADHD in individuals aged 6 and older, aimed at increasing attention and reducing impulsiveness and hyperactivity [11] - The product is scheduled for poster presentations at two major conferences: AACAP in Chicago from October 20-25, 2025, and NEI in Colorado Springs from November 6-9, 2025 [3][4] Group 2: Conference Details - The poster titled "Determining the Optimal Dose of Methylphenidate HCl (JORNAY PM) in Adolescents and Adults in a Real-World Psychiatric Setting" will be presented on October 22, 2025, from 4-6 p.m. CDT at the Hyatt Regency [3] - Another poster titled "JORNAY PM® in Practice: Real-World Evidence Exploration of Utilization and Patient Response" will be presented on November 7, 2025, from 4-5 p.m. MST at Broadmoor West, The Broadmoor [4] Group 3: Company Strategy - Collegium is focused on building a diversified biopharmaceutical company with a strong portfolio in pain management and a growing neuropsychiatry business, with ADHD as a key growth driver [14]

Core Points - Collegium Pharmaceutical, Inc. will celebrate its 10-year anniversary as a publicly traded company by ringing the Nasdaq opening bell on October 14, 2025 [1] - The company has established itself as a leader in responsible pain management and has recently expanded into neuropsychiatry with the acquisition of Jornay PM for ADHD, which is now the fastest growing stimulant medicine for ADHD [2] - Collegium's strategy focuses on growing its commercial portfolio, with Jornay PM as the primary growth driver, while maintaining a disciplined approach to capital deployment [3] Company Overview - Collegium is a diversified biopharmaceutical company dedicated to improving the lives of patients with serious medical conditions, with a strong portfolio in pain management and a growing neuropsychiatry segment [3] - The company is headquartered in Stoughton, Massachusetts, and aims to continue making a positive impact in the healthcare community [3]

Core Insights - Collegium Pharmaceutical, Inc. is celebrating its 10-year anniversary as a publicly traded company on the Nasdaq Stock Market, with a bell-ringing ceremony scheduled for October 14, 2025 [1] - The company has established itself as a leader in responsible pain management and has recently expanded into neuropsychiatry with the acquisition of Jornay PM® for ADHD, which is now the fastest growing stimulant medicine for ADHD treatment [2][3] Company Overview - Collegium is focused on building a diversified biopharmaceutical company aimed at improving the lives of patients with serious medical conditions, with a strong portfolio in pain management and a growing neuropsychiatry segment [3] - The company's strategy includes expanding its commercial portfolio, with Jornay PM as the primary growth driver, and managing capital deployment in a disciplined manner [3]